Analysts Rated AbbVie Inc. (ABBV) as Buy

Abbvie advances as it raises full year outlook

Abbve's third quarter surpassed expectations

AbbVie projects adjusted EPS in the range of $6.37-$6.57 for 2018, showing an approximate 15-19% rally from the mid-point of the revised range of 2017 outlook.

Last month, AbbVie reassured investors that Humira would be safe from competition for at least a few more years, granting rival Amgen Inc a non-exclusive license to sell a copycat version in the United States, but not before 2023. AbbVie Inc. The firm's 50-day moving average price is $89.15 and its 200-day moving average price is $74.55.

The drugmaker's net earnings rose to $1.63 billion or $1.01 per share in the third quarter, from $1.60 billion or 97 cents per share, a year earlier. That compared with consensus estimates from Thomson Reuters of $1.36 in EPS on revenue of $7.0 billion. To assess the reasonability of ABBV's earnings growth per share, we should look at its most recent growth rate delivered. The institutional investor held 6,590 shares of the transportation company at the end of 2017Q2, valued at $603,000, down from 64,796 at the end of the previous reported quarter. During the same period in the prior year, the company earned $1.26 earnings per share.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, November 15th. Moreover, Lodestar Invest Counsel Ltd Liability Company Il has 0.22% invested in AbbVie Inc (NYSE:ABBV) for 23,731 shares. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a yield of 2.86%.

Pain Therapeutics, Inc. (NASDAQ:PTIE) now has a PEG ratio of - where as its P/E ratio is -. Zacks Investment Research raised AbbVie from a sell rating to a hold rating in a research report on Thursday, July 13th.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Goldman Sachs Group, Inc. 71,235 AbbVie Inc (NYSE:ABBV) shares with value of $4.67M were sold by GONZALEZ RICHARD A. Vetr lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating and set a $67.75 price objective for the company.in a report on Wednesday, June 29th.

Geode Capital Management Llc decreased its stake in Rpc Inc (RES) by 3.45% based on its latest 2017Q2 regulatory filing with the SEC. In looking at volatility levels, the shares saw weekly volatility of 3.63% and 2.41% over the past month. Geode Capital Management Llc sold 16,399 shares as the company's stock declined 3.98% while stock markets rallied. SunTrust has "Buy" rating and $95.0 target. DORCHESTER WEALTH MANAGEMENT Co now owns 9,842 shares of the company's stock valued at $641,000 after buying an additional 242 shares in the last quarter. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The company has experienced volume of 2,456,629 shares while on average the company has a capacity of trading 1.08M share. It also reduced Spdr Dow Jones Indl Avrg Etf (DIA) stake by 5,280 shares and now owns 22,630 shares. The disclosure for this sale can be found here.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this news story on another site, it was stolen and republished in violation of United States and global copyright law. On average, equities analysts predict that AbbVie will post $5.53 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in ABBV. Waldron LP lifted its stake in shares of AbbVie by 31.0% in the 1st quarter. Harvest Fund Management Co. It also reduced its holding in Fedex Corp (NYSE:FDX) by 1,567 shares in the quarter, leaving it with 14,059 shares, and cut its stake in Altria Group (NYSE:MO). Ltd now owns 2,227 shares of the company's stock valued at $161,000 after acquiring an additional 2,052 shares during the period. The company has an Average True Range (ATR) value of 2.34, while a Beta Value of 1.54. Tower Research Capital LLC TRC boosted its holdings in AbbVie by 4.7% during the 2nd quarter. Following the completion of the transaction, the insider now directly owns 96,074 shares in the company, valued at $6,733,826.66.

Latest News